LINC00852 and prostate carcinoma: In summary, the above results indicated that overexpression of LINC00852 promoted the proliferation of prostate cancer cells in vivo and in vitro, while knockdown of LINC00852 inhibited the proliferation of prostate cancer cells in vivo and in vitro.